会社概要
- 正式社名: Bioworkshops
- 登録国: China
- 住所: No. 5, Dongwang Road,, Suzhou Industrial Park, Suzhou
- 従業員数: 100 - 249
説明:
A full-service CDMO for antibody products, Bioworkshops offers development and cGMP manufacturing of drug substance and final product, including cell line development, process development, analytical methods, formulation, and process characterization/validation, with 13,000 liters of single-use cell culture capacity (200L to 2000L), three aseptic filling lines for vials, lyophilized products and prefilled syringes/cartridges up to 100,000 units per batch, along with product testing and CTD dossier support.
事業活動
バイオ医薬品
受託製造業者(CMO)早期段階の企業（スタートアップ）
ATC分類(解剖治療化学分類)
受託製造業者(CMO)早期段階の企業（スタートアップ）
先発品原薬
受託製造業者(CMO)早期段階の企業（スタートアップ）
主要製品/サービス
- バイオ医薬品: Trastuzumab emtansine, Trastuzumab deruxtecan, Bedinvetmab, Benralizumab, Bevacizumab, Burosumab, Camrelizumab, Canakinumab, Casirivimab, Cetuximab, Cilgavimab, Daratumumab, Denosumab, Disitamab Vedotin, Dostarlimab, Dulaglutide, Dupilumab, Durvalumab, Eculizumab, Emicizumab, Erenumab, Etesevimab, Evolocumab, Faricimab, Fremanezumab, Frunevetmab, Galcanezumab, Guselkumab, Hyaluronidase Recombinant Human, Imdevimab, Lanadelumab, Lecanemab, Lokivetmab, Mepolizumab, Nirsevimab, Nivolumab, Ocrelizumab, Ofatumumab, Omalizumab, Palivizumab, Panitumumab, Pembrolizumab, Pertuzumab, Polatuzumab, Ramucirumab, Ranibizumab, Ravulizumab, Recombinant Zoster Vaccine, Risankizumab, Rituximab, Romiplostim, Romosozumab, Sarilumab, Sotatercept-csrk, Tezepelumab, Theralizumab, Tixagevimab & Cilgavimab, Tocilizumab, Trastuzumab, Ustekinumab, Adalimumab, Anifrolumab, Atezolizumab, Bamlanivimab, Bebtelovimab
- バイオ医薬品サービス: Cell Line Development, GMP manufacturing for cell culture products
- ATC分類(解剖治療化学分類): Respiratory Syncytial Virus Vaccine
当社の製品・サービス
Sell · Biopharmaceutical Products
認証
証明
CPHI & PMEC China 2026
06/2026 – 06/2026
CPHI & PMEC China 2026
評価
(0)
(0)
(0)
(0)
(0)
コメント
フィルター:
並べ替え:
コメントはありません。
評価とコメントを残す